Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC).
Authors: Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 24
Issue: 18
Pages: 147S
eISSN: 1527-7755
ISSN: 0732-183X
Source: Web of Science (Lite)
Preferred by: Tamas Hickish